AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company, announced on Thursday that it has completed patient enrolment in two Phase II clinical trials of AHB-137 to treat chronic hepatitis B (CHB).

The product is a leading candidate being assessed in the Phase II study AB-10-8007 (NCT07069569).

AB-10-8007, a randomised, open-label, multicentre study, will assess the efficacy and safety of AHB-137 Injection along with either a hepatitis B vaccine or pegylated interferon alpha-2b (Peg-IFN) in subjects with HBeAg-negative CHB receiving nucleos(t)ide analogue (NA) therapy.

Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, said, 'Combination therapies have historically been a key to treat or cure chronic viral infections, including HIV and HCV. The AB-10-8007 study aims to combine AHB-137 with approved HBV treatments to further increase functional cure rates, while the AB-10-8008 study explores the potential to expand AHB-137 treatment to a broader patient population. Together, these studies could further establish AHB-137 as the potential backbone therapy for HBV functional cure. We look forward to sharing interim results at international conferences throughout 2026.'